Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).
Crawford
J
J
Duke University Medical Center, Durham, NC, USA.
Duch
D S
DS
Gralla
R J
RJ
Hillner
B E
BE
Hollen
P J
PJ
Vokes
E E
EE
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003365:Costs and Cost Analysis; D016527:Drug Costs; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011788:Quality of Life; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents